Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Mrinal M. Patnaik, MBBS, Emnet A Wassie, MD, Eric Padron, MD, Francesco Onida, MD, Raphael Itzykson, Terra L Lasho, PhD, Olivier Kosmider, MD PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett Ketterling, MD, Rami S Komrokji, MD, Ayalew Tefferi, MD, Eric Solary

Blood (2014) 124 (21): 4633.

https://doi.org/10.1182/blood.V124.21.4633.4633

Published: 2014

Journal Articles

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A. Abdelrahman, MBBCh, Christy Finke, BS, Terra L Lasho, PhD, Kebede Begna, MD, Aref Al-Kali, MD, William J. Hogan, MBChB, Mark R. Litzow, MD, Curtis A. Hanson, MD, Rhett Ketterling, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 3162.

https://doi.org/10.1182/blood.V124.21.3162.3162

Published: 2014

Journal Articles

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Ayalew Tefferi, MD, Terra L Lasho, PhD, Alexander Tischer, PhD, Emnet A Wassie, MD, Christy Finke, BS, Alem A Belachew, Rhett Ketterling, MD, Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 3166.

https://doi.org/10.1182/blood.V124.21.3166.3166

Published: 2014

Journal Articles

Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study

Emnet A Wassie, MD, Raphael Itzykson, Terra L Lasho, PhD, Olivier Kosmider, MD PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett Ketterling, MD, Eric Solary, Ayalew Tefferi, MD, Mrinal M. Patnaik, MBBS

Blood (2014) 124 (21): 412.

https://doi.org/10.1182/blood.V124.21.412.412

Published: 2014

Journal Articles

Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients

Ayalew Tefferi, MD, Emnet A Wassie, MD, Kebede Begna, MD, Christy Finke, BS, Alem A Belachew, Naseema Gangat, MD, Terra L Lasho, PhD, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Rhett Ketterling, MD

Blood (2014) 124 (21): 631.

https://doi.org/10.1182/blood.V124.21.631.631

Published: 2014

Journal Articles

Blast Transformation in Chronic Myelomonocytic Leukemia: Risk Factors and Outcome

Mrinal M. Patnaik, MBBS, Emnet A Wassie, MD, Terra L Lasho, PhD, Curtis A. Hanson, MD, Rhett Ketterling, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1932.

https://doi.org/10.1182/blood.V124.21.1932.1932

Published: 2014

Journal Articles

Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma

Jonas Paludo, MD, Nishanth Vallumsetla, MBBS, Shaji Kumar, MD, Rhett Ketterling, MD, Morie A Gertz, MD MACP, Angela Dispenzieri, MD, Martha Q Lacy, MD, Francis K Buadi, MD, David Dingli, MD, PhD, Utkarsh Painuly, MD, Nelson Leung, MD, Robert Kyle, MD MACP, S. Vincent Rajkumar, MD, Prashant Kapoor, MD

Blood (2014) 124 (21): 2059.

https://doi.org/10.1182/blood.V124.21.2059.2059

Published: 2014

Journal Articles

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

Blood (2014) 124 (21): 405.

https://doi.org/10.1182/blood.V124.21.405.405

Published: 2014

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

Journal Articles

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, PhDMD, Christy Finke, BS, Terra L Lasho, PhD, Naseema Gangat, MD, Rhett Ketterling, MD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 406.

https://doi.org/10.1182/blood.V124.21.406.406

Published: 2014

Journal Articles

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

Thomas Prebet, MD, PhD, Zhuoxin Sun, PhD, Rhett Ketterling, MD, Peter L. Greenberg, MD, Amer M. Zeidan, MD, Mark R. Litzow, MD, Janice L. Gabrilove, MD, Harry Paul Erba, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, MD, PhD, Steven D Gore, Martin S Tallman, MD

Blood (2013) 122 (21): 2777.

https://doi.org/10.1182/blood.V122.21.2777.2777

Published: 2013

Journal Articles

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

Sania S Raza, MD, David Viswanatha, MD, Lori A Erickson, MD, Terra L Lasho, MT(ASCP), Christy Finke, BS, Ryan A Knudson, Rhett Ketterling, MD, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3840.

https://doi.org/10.1182/blood.V118.21.3840.3840

Published: 2011

Journal Articles

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Blood (2010) 116 (21): 851.

https://doi.org/10.1182/blood.V116.21.851.851

Published: 2010

Journal Articles

Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia

Huimin Geng, PhD, Donna Neuberg, ScD, Elisabeth Paietta, PhD, Xutao Deng, PhD, Yushan Li, Yuan Xin, Janis Racevskis, PhD, Rhett Ketterling, MD, Susan M Richards, PhD, Martin S. Tallman, MD, Jacob M. Rowe, MD, Mark R. Litzow, MD, Olivier Elemento, PhD, Ari M. Melnick

Blood (2010) 116 (21): 852.

https://doi.org/10.1182/blood.V116.21.852.852

Published: 2010

Journal Articles

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

Domenica Caramazza, Terra Lasho, MT, (ASCP), Christy Finke, Naseema Gangat, David Dingli, M.D., Ph.D., Ryan Knudson, Sergio Siragusa, MD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Rhett Ketterling, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4009.

https://doi.org/10.1182/blood.V116.21.4009.4009

Published: 2010

Journal Articles

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Thomas Prebet, M.D., Ph.D., Zhuoxin Sun, PhD, Rhett Ketterling, Gary Hicks, Ph.D., C.L. Beach, PharmD, Peter L. Greenberg, MD, Elisabeth Paietta, PhD, Magdalena Czader, M.D., Ph.D., Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD, Steven D. Gore, M.D.

Blood (2010) 116 (21): 4013.

https://doi.org/10.1182/blood.V116.21.4013.4013

Published: 2010

Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD

Blood (2010) 116 (21): 3315.

https://doi.org/10.1182/blood.V116.21.3315.3315

Published: 2010

NARROW

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study

Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients

Blast Transformation in Chronic Myelomonocytic Leukemia: Risk Factors and Outcome

Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis

Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study

TP53 mutations and Polymorphisms in Primary Myelofibrosis,

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only